Manoj Kumar Mahapatra

Employment

• Kanak Manjari Institute of Pharmaceutical Sciences Associate Professor
  2016 - 2025
• Royal College of Pharmacy and Health Sciences Asst. Professor
  2009 - 2012

Education

• University Inst. of Pharmaceutical Sciences, Panjab University PhD (Pharmaceutical Chemistry)
  2012 - 2016
• Birla Institute of Technology M. Pharm (Pharmaceutical Chemistry)
  2007 - 2009
• Roland Institute of Pharmaceutical Sciences B. Pharm (Bachelor of Pharmacy)
  2003 - 2007

Projects & Funding

Projects & funding information is unavailable.

Publications (27)

• Integrated use of ligand and structure-based virtual screening, molecular dynamics, free energy calculation and ADME prediction for the identification of potential PTP1B inhibitors
  Molecular Diversity 2024 DOI: 10.1007/S11030-023-10608-8
  +Save
• Nano-based drug delivery of anticancer agents
  Green Approaches in Medicinal Chemistry for Sustainable Drug Design 2024 DOI: 10.1016/B978-0-443-16164-3.00002-9
  +Save
• Repurposing DPP-4 Inhibitors as a Novel Intervention in COVID-19: In Silico Analysis for SARS-CoV-2 Spike Glycoprotein Inhibition
  Proceedings of the National Academy of Sciences, India Section B: Biological Sciences 2024 DOI: 10.1007/S40011-024-01575-7
  +Save
• Computational approaches for development of anti-COVID-19 agents
  Green Approaches in Medicinal Chemistry for Sustainable Drug Design 2024 DOI: 10.1016/B978-0-443-16164-3.00022-4
  +Save
• BMaps: A Web Application for Fragment-Based Drug Design and Compound Binding Evaluation
  Journal of Chemical Information and Modeling 2023 DOI: 10.1021/ACS.JCIM.3C00209
  +Save
• Greener Approaches for Synthesis of Bioactive Thiadiazole Scaffolds
  Current Organocatalysis 2023 DOI: 10.2174/2213337210666230210142303
  +Save
• Fundamental considerations in drug design
  Computer Aided Drug Design (CADD): From Ligand-Based Methods to Structure-Based Approaches 2022 DOI: 10.1016/B978-0-323-90608-1.00005-8
  +Save
• Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes
  Reviews in Endocrine and Metabolic Disorders 2022 DOI: 10.1007/S11154-021-09699-1
  +Save
• Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review
  Pharmaceutical Research 2022 DOI: 10.1007/S11095-022-03302-1
  +Save
• Synthesis and Anti-hyperglycaemic Study of Aryl Sulfonate Ester Conjugated 5-arylidene-thiazolidine-2,4-diones
  Indian Journal of Pharmaceutical Education and Research 2021 DOI: 10.5530/ijper.55.3.164
  +Save